Invivyd (IVVD) chief scientific officer Allen sells $27k in stock

Invivyd, Inc. (NASDAQ:IVVD) Chief Scientific Officer Robert D. Allen III, recently sold shares of the company’s common stock for a total of $27,572. The transactions come as the $85 million market cap company has seen its stock decline 28% in the past week. According to a Form 4 filing with the Securities and Exchange Commission, the sales occurred in two separate transactions at prices ranging from $0.5666 to $0.6502. InvestingPro analysis suggests the stock is currently undervalued, despite maintaining impressive gross profit margins of 93%.

On August 18, 2025, Allen sold 18,512 shares at a price of $0.6502 per share. The total value of this transaction was $12,036. On August 19, 2025, he sold an additional 27,420 shares at $0.5666, for $15,536.

On August 15, Allen also acquired 99,000 shares of Common Stock upon the exercise of Restricted Stock Units.

In other recent news, Invivyd, Inc. received FDA guidance on a potential Biologics License Application pathway for its monoclonal antibody candidate VYD2311, aimed at preventing COVID-19. The FDA has agreed that a single Phase 2/3 trial could support a BLA submission, with the primary goal of reducing symptomatic COVID-19 cases. Additionally, H.C. Wainwright has maintained its Buy rating for Invivyd, highlighting the regulatory path for VYD2311 as a significant factor. In another development, Invivyd announced that its monoclonal antibody PEMGARDA continues to show neutralizing activity against the XFG variant, which is contributing to a new wave of COVID-19 infections in the U.S.

The company also reported that both PEMGARDA and VYD2311 are effective against other variants, including NB.1.8.1, LF.7.9, and LP.8.1. Furthermore, Invivyd has formed the SPEAR Study Group to explore the benefits of monoclonal antibodies in treating Long COVID and Post-Vaccination Syndrome. This research initiative includes experts from institutions such as the University of California, San Francisco, and Mount Sinai. In related news, Yale immunobiologist Akiko Iwasaki has joined Invivyd’s research group, contributing her expertise in viral pathogenesis and immunobiology.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.